SCHEMBL7704902

SCHEMBL7704902

CC1=C(N)Nc2cc(CN(Cc3cccc(Cl)c3)C(=O)OC(C)(C)C)ccc2O1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.37
HDAC1 Q13547 2/20 0.36
HDAC3 O15379 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
GHSR Q92847 3/20 0.33
CTSL P07711 1/20 0.33
SLC2A1 P11166 1/20 0.33
AOC3 Q16853 1/20 0.33
KDM4E B2RXH2 1/20 0.33
FFAR1 O14842 1/20 0.32
FFAR4 Q5NUL3 1/20 0.32
PKM P14618 1/20 0.32
MAP2K2 P36507 1/20 0.32
CALCRL Q16602 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TACR1 P25103 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704965 0.92 HDAC3 (0.36) HDAC1HDAC3HDAC2NCOR2
SCHEMBL7704910 0.91 HDAC1 (0.45) HDAC1HDAC3HDAC2NCOR2SMN1; SMN2
SCHEMBL7711248 0.89 RIPK1 (0.37) RIPK1HDAC1HDAC3HDAC2NCOR2
SCHEMBL7711458 0.89 HDAC3 (0.33) HDAC1HDAC3HDAC2NCOR2SMN1; SMN2
SCHEMBL7708018 0.88 ERCC1 (0.33) HDAC1HDAC3HDAC2NCOR2SMN1; SMN2
SCHEMBL7704988 0.88 HDAC3 (0.36) HDAC1HDAC3HDAC2NCOR2SMN1; SMN2
SCHEMBL7704872 0.88 HSD17B2 (0.38) HDAC1HDAC3HDAC2NCOR2SLC2A1
SCHEMBL7708189 0.88 HDAC3 (0.37) HDAC1HDAC3HDAC2NCOR2SMN1; SMN2
SCHEMBL7711366 0.88 HDAC1 (0.37) HDAC1HDAC3HDAC2NCOR2SMN1; SMN2
SCHEMBL7711360 0.87 TRPM8 (0.36) HDAC1HDAC3HDAC2NCOR2SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed